Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
A combination of vitamin D, omega-3 and exercise can produce a small protective effect on biological aging, according to a recent study.
read more
In a deal worth approximately $935 million, Jazz will pick up a novel first-in-class treatment for rare pediatric brain tumors with an August PDUFA date.
read more
The drugmaker will discontinue its phase 3 development program evaluating aticaprant as an add-on treatment for major depressive disorder.
read more
Taro Pharmaceuticals and Lupin have received U.S. FDA approvals for generic versions of Bayer’s Xarelto (rivaroxaban) 2.5 mg tablets.
read more
Pharmacokinetic data suggested that the neflamapimod capsules used during the initial trial —
from an older batch — may have had lower bioavailability.
read more
The Swiss-Dutch health and nutrition company has introduced a new portfolio of taste solutions specifically designed for use in pharma formulations.
read more
Proceeds will support the continued clinical development of the company's TEAD autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma.
read more
The drugmakers will combine their generics businesses and Endo's sterile injectables business and intend to eventually separate the combined unit.
read more
The partners expect to file an IND for first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet for obesity later this year.
read more
According to study from BCC Research, global softgel capsules market is expected to grow from $7.9 billion in 2024 to $11.5 billion by the end of 2029.
read more
The study compared an oral version of Eli Lilly’s Zepbound, created with Lexaria’s patented drug delivery technology, to conventional injected Zepbound.
read more
The nod marks the third FDA approval for oral Fabhalta and the first and only treatment approved in C3 glomerulopathy.
read more
The partners received a second CRL from the FDA regarding their combination treatment of rivoceranib and camrelizumab for hepatocellular carcinoma.
read more
The Vancouver-based biotech prepares to initiate a phase 1/2a clinical trial for its MEAI-based oral drug candidate in the U.S. and Israel.
read more
The oversubscribed financing was co-led by Novo Holdings and Jeito Capital and supported by existing investors, including Eli Lilly.
read more